1346814-90-1

Basic information

• Product Name: 3-(1-(2-chloro-5-fluorophenyl)ethoxy)-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-amine
• CAS NO: 1346814-90-1
• Molecular Weight: 346.792
• Mol File: 1346814-90-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(1-(2-chloro-5-fluorophenyl)ethoxy)-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-(2-chloro-5-fluorophenyl)ethoxy)-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-amine(1346814-90-1)
• EPA Substance Registry System: 3-(1-(2-chloro-5-fluorophenyl)ethoxy)-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-amine(1346814-90-1)

Safety Data

• Hazardous Substances Data: 1346814-90-1(Hazardous Substances Data)

Upstream product

• 1346818-11-8 3-[1-(2-chloro-5-fluorophenyl)ethoxy]-5-bromo-2-aminopyridine 
• 2965-16-4 1-(2-chloro-5-fluorophenyl)ethan-1-one 
• 700-31-2 (RS)-1-(2-chloro-5-fluorophenyl)ethanol 
• 74115-13-2 5-bromopyridine-3-ol 
• 691872-15-8 5-bromo-3-hydroxy-2-nitropyridine 

Relevant articles and documents

Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors

The abnormal activation of JAK2 kinase is closely related to the occurrence and progression of myeloproliferative neoplasms (MPNs). At present, there is still an obvious unmet medical need for selective JAK2 inhibitors in clinic. In this paper, a class of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors was obtained by combining drug design, synthesis and structure-activity relationship studies based on the previously identified lead Crizotinib. Among them, 21b exhibited high inhibitory activity against JAK2 with an IC50 of 9 9 nmol/L, moreover, it showed 276- and 184-fold selectivity over JAK1 and JAK3, respectively. Besides, 21b had a significant antiproliferative activity against HEL cells, and also inhibited the phosphorylation of JAK2 and its down-stream signaling pathway. These results indicated that 2-aminopyridine compound 21b had the potential to be developed as a selective JAK2 inhibitor for further study.

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.